Physician profile

Robert Jerzy Krasowski

Cardiovascular Disease · High Point, NC

NPI 1346209699

$8,686.89

in general payments reported to CMS, 2019-2025

40 companies · $915 in 2025

The $915 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,151.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $899.94 2019-2025
Janssen Pharmaceuticals, INC $825.42 2019-2024 Xarelto
Amgen INC. $653.93 2019-2025 Repatha, Repatha
Merck Sharp & Dohme LLC $611.29 2021-2025 Verquvo, Capvaxive
Pfizer INC. $610.27 2019-2025
Sanofi-Aventis U.S. LLC $546.29 2019-2024
E.R. Squibb & Sons, L.L.C. $416.90 2019-2025 Eliquis, Camzyos
Astrazeneca Pharmaceuticals LP $415.93 2019-2025 Farxiga
Irhythm Technologies, INC. $391.18 2019-2024 Zio Xt Patch, Zio Monitor, Zio At Patch
Esperion Therapeutics, INC. $383.42 2021-2025 Nexletol
Bayer Healthcare Pharmaceuticals INC. $355.53 2022-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $327.30 2019-2025 Lifevest
Novo Nordisk INC $324.76 2021-2025 Wegovy, Ozempic
Boehringer Ingelheim Pharmaceuticals, INC. $232.47 2019-2025 Jardiance
Cvrx, INC. $211.02 2019-2024 Barostim Neo System
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Heartflow, INC. $177.89 2023-2024 Ffrct
Amarin Pharma, INC. $168.31 2019-2022
Abbott Laboratories $153.62 2020-2025 Thoratec Heartmate 3 Lvas Implant Kit
Boston Scientific Corporation $112.28 2019-2023 Watchman Flx, Watchman Access System
Scpharmaceuticals INC. $102.91 2024-2025
Lundbeck LLC $90.87 2019-2020
Actelion Pharmaceuticals US, INC. $72.83 2019-2022
Medtronic, INC. $71.13 2021-2022
Regeneron Healthcare Solutions, INC. $66.99 2019
Baxter Healthcare $61.99 2023 Hillrom - Cardiac Ambulatory Monitor
Lexicon Pharmaceuticals, INC. $57.08 2024 Inpefa
Gilead Sciences, INC. $46.98 2019
Lilly USA, LLC $39.62 2025 Zepbound
Impulse Dynamics (USA) INC. $29.79 2023 Optimizer
Philips North America LLC $27.71 2023
Kestra Medical Technology Services, INC. $25.02 2024 Assure Wcd
Kowa Pharmaceuticals America, INC. $24.44 2019-2021
Portola Pharmaceuticals, LLC $23.34 2019
Agepha Pharma Fz LLC $22.44 2025 Lodoco
Shield Therapeutics INC $21.19 2023 Accrufer
Vifor Pharma, INC. $20.19 2022
Biotronik INC. $18.10 2025 Acticor 7 Vr-T Dx
Cashflow Solutions, LLC $16.82 2025 Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White
Bardy Diagnostics, INC. $15.00 2019
Kiniksa Pharmaceuticals International, Plc $14.70 2024 Arcalyst

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Jerzy Krasowski

$8,686.89

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $915 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/332465/robert-jerzy-krasowski

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.